NDAOPHTHALMICSOLUTION/DROPS
Approved
Aug 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Mechanism of Action
cystine-depleting agent by converting cystine to cysteine and cysteine-cysteamine mixed disulfides and reduces corneal cystine crystal accumulation.
Clinical Trials (2)
Cystadrops in Pediatric Cystinosis Patients From Six Months to Less Than Two Years Old (SCOB2)
Started Sep 2020
5 enrolled
Cystinosis
Randomized Study of New Formulation Ophthalmic Cysteamine Hydrochloride for Corneal Cystine Accumulation in Patients With Cystinosis
Started Dec 1999
30 enrolled
Cystinosis